Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell published : This year save search
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Published: 2024-04-22 (Crawled : 17:00) - globenewswire.com
PHIO | News | $0.6709 -19.16% -23.7% 640K
|
Health Technology
|
| O: -1.56%
H: 66.67%
C: 31.75%
ph-762 tumor injection growth
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.831 -5.57% -5.9% 84K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.772 5.15% 4.9% 670K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
INAB | $1.035 3.51% 3.39% 280K
|
|
| O: 6.42%
H: 1.72%
C: -5.17%
cell preclinical for therapy platform
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
ITOS | $11.0 1.95% 1.91% 300K
|
Health Technology
|
| O: -1.0%
H: 2.26%
C: -1.29%
eos-984 association cancer cell research preclinical for meeting
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $9.34 -4.11% -4.28% 19K
|
| Email alert
Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.781 -1.14% -1.15% 110K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CTMX | $1.68 0.6% 0.6% 290K
|
Health Technology
|
| O: -0.47%
H: 2.35%
C: 0.94%
probody candidate t-cell collaboration therapeutics
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 7.14%
H: 1.9%
C: -0.95%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -7.41%
t-cell expansion vision therapy platform
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
Published: 2024-03-18 (Crawled : 16:00) - biospace.com/
CTMX | $1.68 0.6% 0.6% 290K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody t-cell collaboration therapeutics milestone
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2024-03-18 (Crawled : 12:30) - prnewswire.com
CTXR | $0.772 5.15% 4.9% 670K
|
Health Technology
|
| O: -2.23%
H: 11.11%
C: 0.03%
fda t-cell resubmission treatment pharmaceuticals
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
CTMX | $1.68 0.6% 0.6% 290K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody collaboration therapeutics milestone
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Published: 2024-03-06 (Crawled : 15:30) - biospace.com/
MRUS | $40.75 0.74% 0.74% 570K
|
Health Technology
|
| O: 0.06%
H: 1.66%
C: -2.56%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.15%
H: 0.6%
C: -0.34%
t-cell collaboration
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
CRBU | $3.98 -0.25% -0.25% 930K
|
Health Technology
|
| O: 1.63%
H: 0.54%
C: -0.67%
cb-012 association cancer cell research preclinical meeting car-t
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
NXTC | $1.53 -4.97% -5.23% 90K
|
Health Technology
|
| O: -5.76%
H: 7.22%
C: 5.56%
cell preclinical
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
COYA | News | $7.995 0.06% 0.06% 24K
|
|
| O: 0.0%
H: 1.1%
C: -5.86%
conference cell dementia system therapeutics
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
VIRX | $0.831 -5.57% -5.9% 84K
|
Manufacturing
|
| O: 0.0%
H: 3.37%
C: -8.43%
t-cell trial therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.